Home › FDA Decisions › GSK 2025-12-11

GSK FDA Decision Approved · 2025-12-11

Updated September 23, 2026·next FDA decision on the calendar

Price into the decision (T-120)

Daily close, T-120 (6/26/25) through T+5. Run-up high $48.97 on 12/3/25, low $36.2 on 7/23/25 (T-120 to T-1). FDA decision 12/11/25. Historical price action, not a forecast.

Decision facts

FDA decision date2025-12-11

DrugBlujepa (gepotidacin)

IndicationUncomplicated urogenital gonorrhoea in patients 12 years of age and older

Outcome✓ Approvedprimary-sourced

Decision-day move+1.0%

T-120 run-up (low→high)+30.0% ($37.71→$48.97)

ValidationVerified 2026-08-12: Drugs@FDA, application NDA218230, action date 2025-12-11

Market-cap tierLarge

Cohort decision-day move (history)1.0% median (n=835)

Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.

See the full 2026 PDUFA calendar →

Questions

Was Blujepa (gepotidacin) approved by the FDA?

Yes. The FDA approved the application for Blujepa (gepotidacin) on December 11, 2025. The primary source is linked on this page.

What was Blujepa (gepotidacin) under FDA review for?

The application covered Uncomplicated urogenital gonorrhoea in patients 12 years of age and older. The FDA approved the application on December 11, 2025.

How did GSK stock react to the FDA decision?

On the decision day GSK moved +1.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.